Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-Cell Non-Hodgkin Lymphoma
Cellular Biomedicine Group Inc. announced results from an ongoing Phase IIa clinical trial evaluating the safety, feasibility and anti-tumor activity of its acquired chimeric antigen receptor-modified T-cells (CAR-T) immunotherapy (CBM-CD20.1) targeting CD20 for the treatment of patients with advanced B-cell non-Hodgkin lymphoma.
SELLAS Life Sciences Reports Promising Top-Line Phase II Data for WT1 Vaccine in Mesothelioma and Acute Myeloid Leukemia Patients
SELLAS Life Sciences Group announced top-line data from the company’s Phase II clinical study of its WT1 cancer vaccine in patients with malignant pleural mesothelioma.
Kiadis Pharma Announces Initiation of a Repeat-Dosing Phase II Clinical Trial with ATIR101™
Kiadis Pharma announced that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™.
Seattle Genetics Announces Initiation of Phase I/II Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-Line Hodgkin Lymphoma
Seattle Genetics, Inc. announced that it has initiated a Phase I/II clinical trial of ADCETRIS in combination with Opdivo for patients with relapsed or refractory Hodgkin lymphoma after failure of frontline treatment.
Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia
Bio-Path Holdings, Inc. announced the successful completion of Cohort 7 of its Phase Ib clinical trial evaluating the toxicity of its lead compound, liposomal Grb-2, combined with low-dose cytarabine chemotherapy in patients with advanced acute myeloid leukemia.